# DESCRIPTION

## FIELD OF INVENTION

- relate invention to cancer treatment

## BACKGROUND

- describe cancer etiologies
- discuss apoptosis regulation

## SUMMARY

- introduce cancer treatment method
- describe P2X7 agonist administration
- outline method embodiments
- summarize cancer treatment approaches

## DEFINITIONS

- define cancer
- define inhibit proliferation of cancer cell
- define detecting
- define diagnosing
- define tumor
- define precancerous
- define tumor-cell killing
- define anti-P2X7 antibody
- define immunoassay
- define specifically binds to an antibody
- define cancer symptoms
- define suspected
- define in need of a diagnosis
- define in need of a treatment
- define local
- define detecting
- define diagnosing
- define tumor
- define precancerous
- define at risk for
- define effective amount
- define reduce
- define inhibitory compound

## DETAILED DESCRIPTION OF THE INVENTION

- introduce cancer treatment method
- describe P2X7 receptor agonist role in apoptosis
- contemplate composition and embodiments

### I. Cancer

- define cancer
- describe causes and types of cancer
- discuss symptoms and tests
- introduce conventional treatment
- contemplate epithelial cancers

### II. Apoptosis

- introduce apoptosis concept
- describe apoptosis process
- discuss advantages of apoptosis
- describe DNA fragmentation and chromatin condensation
- introduce caspase family of proteases
- describe intrinsic mitochondrial pathway
- describe extrinsic death-receptor pathway
- discuss crosstalk between pathways
- contemplate targeted therapies
- discuss limitations of current therapies
- describe role of defective apoptosis in cancer
- discuss selective induction of apoptosis in cancer cells
- contemplate P2X7 receptor expression in cancer cells

### II. P2X Receptor Family

- introduce P2X7 receptor gene localization
- describe genetic mutations in P2X7 receptor gene
- motivate P2X7 receptor as a ligand-operated channel
- summarize ATP as a naturally occurring P2X7 receptor ligand
- describe P2X7 receptor activation and apoptosis
- discuss P2X7 receptor pore formation and Ca2+ influx
- summarize P2X7 receptor expression in proliferating cells
- motivate P2X7 receptor role in cell growth regulation
- discuss P2X7-mediated apoptosis and intracellular signaling
- summarize P2X7 receptor expression in normal and cancer tissues
- describe P2X7 receptor role in epidermal growth control
- discuss P2X7 receptor structure and topology
- summarize P2X7 receptor glycosylation and trafficking
- motivate P2X7 receptor activation and signaling pathways
- discuss P2X7 receptor regulation and control mechanisms
- summarize P2X7 receptor transcription and post-transcriptional regulation
- introduce P2X receptor family
- describe regulation of P2X7 receptor by PARP and miRNAs
- explain regulation of receptor glycosylation
- discuss regulation of receptor oligomerization
- describe estrogen regulation of P2X7-mediated apoptosis
- summarize biological effects of P2X7 receptor activation
- describe role of P2X7 in normal epithelial cell growth
- explain P2X7 receptor expression in normal stratifying epithelia
- describe P2X7 receptor expression in cancer epithelial cells
- discuss differences in P2X7 receptor expression between normal and cancer cells
- explain P2X7 polymorphisms and point-mutations
- describe epigenetic control of P2X7 receptor expression in cancer cells
- discuss hypermethylation of P2X7 promoter in cancer cells
- explain regulation of P2X7 transcript stability by micro-RNAs
- describe regulation of P2X7 receptor glycosylation in cancer cells
- discuss role of splicing variants in P2X7 receptor function

### III. Cancer Treatment

- introduce cancer treatment using P2X7 receptor
- motivate P2X7 receptor as anti-neoplastic modality
- summarize ATP treatment in patients with advanced cancers
- describe limitations of systemic ATP administration
- explain instability of ATP
- introduce BzATP as P2X7 receptor agonist
- describe properties of BzATP
- summarize effects of BzATP on P2X7 receptor
- describe specificity of BzATP for P2X7 receptor
- introduce local application of BzATP on skin
- summarize effects of BzATP on skin papillomas and cancers
- describe mechanism of BzATP-induced apoptosis
- introduce method for treating and preventing cancer
- describe method for modulating growth of epidermal cells
- introduce anti-cancer agent screening using DMBA/TPA mouse model
- describe effects of BzATP on papilloma formation
- introduce method for treating human epithelial cancers
- describe composition for inhibiting growth and progression of epithelial lesions
- introduce cancer treatment
- describe P2X7 receptor expression in normal cells
- describe P2X7 receptor expression in human epidermal squamous cell carcinoma-9 cells
- describe P2X7 receptor expression in mouse skin cancer cells
- describe effects of BzATP on P2X7 expression and apoptosis
- describe morphological effects of BzATP on papilloma formation
- describe effects of BzATP on cancer development and progression
- introduce P2X7-mediated cell apoptosis
- describe in vitro effects of exogenous BzATP on apoptosis
- describe in vitro recombinant P2X7 expression and apoptosis
- describe in vivo BzATP effects on normal tissues
- describe P2X7 receptor expression in normal epidermal cells and cultured cells
- describe P2X7-mediated apoptosis in controlling growth of epithelial cells
- introduce cancer treatment
- describe in vivo tolerability of BzATP
- describe short-term effects of BzATP
- describe long-term effects of BzATP
- describe in vivo effects of BzATP on cancerous tissue development
- describe DMBA/TPA skin neoplasia model
- describe BzATP co-treatment with DMBA/TPA
- analyze papilloma development
- analyze papilloma size
- describe papilloma characteristics
- describe involution of papillomas
- describe progression to squamous spindle-cell carcinomas
- analyze skin lesions over time
- analyze proportion of living animals with papillomas
- analyze proportion of living animals with cancerous lesions
- describe cancer treatment
- compare lesion sizes
- analyze data on cancerous lesions
- describe survival curves
- introduce P2X7 receptor expression
- describe BzATP-augmented apoptosis
- analyze calcium pore formation
- measure cytosolic calcium levels
- measure ethidium bromide influx
- analyze effects of P2X7-receptor anti-sense oligonucleotide
- describe extracellular calcium dependence
- analyze effects on cellular proliferation
- describe effects on normal skin
- describe effects on papilloma tissues
- analyze P2X7 receptor expression in cancer cells
- describe relationship between P2X7 receptor and apoptosis
- summarize experimental findings
- discuss implications of P2X7 receptor expression

### IV. P2X7 Receptor Expression Regulation

- contemplate upregulating P2X7 receptor expression
- treat and/or prevent cancer by increasing P2X7 receptor cell surface density
- elucidate active promoter region and Transcription Initiation Start Site
- define active promoter region using cDNA fragments and luciferase vector
- elucidate Transcription Initiation Start Site using modified 5â€² RACE method
- identify regions distal to TpIS that inhibit transcription
- demonstrate demethylation increases P2X7 receptor expression and apoptosis
- evaluate effects of changes in methylation status on P2X7 transcription
- analyze CpG sites and P2X7 gene methylation status
- introduce P2X7 receptor expression regulation
- evaluate CpG sites downstream of P2X7 promoter
- determine effect of CpG site mutations on luciferase activity
- analyze methylation status of CpG sites in normal and cancer cells
- compare methylation status between normal and cancer cells
- demonstrate hypermethylation of CpG sites in cancer cells
- identify protein binding sites in P2X7 enhancer regions
- describe P2X7 expression regulator proteins
- discuss role of p300, Elk-1, E47, E11aE, E2F, and p53 in P2X7
- propose method for treating and preventing cancer
- summarize data on P2X7 transcription regulation
- discuss regulation of P2X7 receptor expression
- describe association between P2X7 receptor and p53 apoptotic pathway
- conclude on reduced expression of P2X7 receptor in cancer cells

### V. Administration of P2X7 Receptor Agonists

- describe administration routes
- introduce liposomes for delivery
- describe liposome composition
- motivate targeting cancer cells
- describe opsonization-inhibition moieties
- explain stealth liposomes

### VI. P2X7 Receptor Agonist Pharmaceutical Formulations

- describe pharmaceutical composition preparation
- list pharmaceutical formulation components

## EXPERIMENTAL

- list materials and methods

### Human Keratinocyte Cell Cultures and Transfections

- describe cell cultures and transfections

### Protein Assays

- describe protein assays

### P2X7 mRNA in-situ Hybridization

- describe in-situ hybridization

### Real-Time PCR

- describe real-time PCR

### Example V

- describe ATP assays
- describe apoptosis assays
- describe P2X7-antisense oligonucleotides
- describe animal experiments
- detail DMBA/TPA treatment
- detail BzATP treatment
- describe skin neoplasia induction
- describe skin lesion evaluation
- describe blood sample analysis
- describe cancerous lesion evaluation
- describe P2X7 immunoreactivity
- describe BzATP effects on apoptosis
- describe ALT and AST assays
- describe data analysis
- describe mouse keratinocyte cell culture
- describe cytosolic calcium and ethidium-bromide assays
- describe in vivo treatment of mice with BzATP
- discuss results of BzATP treatment
- introduce cell cultures
- describe generation of primary cultures
- describe cell culture conditions
- elucidate promoter region of P2X7 gene
- describe PCR and ligation of promoter region
- elucidate transcription initiation start site
- describe mutagenesis of CpG sites
- describe P2X7-receptor immunostaining
- describe apoptosis assays
- describe in vitro methylation assays
- describe electrophoretic mobility shift assay
- describe DNA methylation analysis
- describe data analysis

